The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
Open accessAbstract
We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 3×
“TILs have been shown to mediate regression of metastatic melanoma in patients treated with TILs plus IL-2 (26).”
BackgroundInfluentialSelf-citationTownsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,699
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Eisinger, M., & Marko, O. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2018 · Cited by 549
Parham, P., & Brodsky, F. M. (1981) · Human Immunology · doi:10.1016/0198-8859(81)90065-3 · Cited by 320
Vitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1338 · Cited by 257
te Riele, H., Maandag, E. R., Clarke, A., Hooper, M., & Berns, A. (1990) · Nature · doi:10.1038/348649a0 · Cited by 239
Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2
PARHAM, P., & BODMER, W. F. (1978) · Nature · doi:10.1038/276397a0 · Cited by 236
Darrow, T. L., Slingluff, C. L., & Seigler, H. F. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.9.3329 · Cited by 214
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.
Vijayasaradhi, S., Bouchard, B., & Houghton, A. N. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.4.1375 · Cited by 207
Prognostic significance of hypopigmentation in malignant melanoma
Bystryn, J. ‐. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.8.1053 · Cited by 176
Prognostic Significance of Hypopigmentation in Malignant Melanoma
Bystryn, J.-C. (1987) · Archives of Dermatology · doi:10.1001/archderm.1987.01660320095019 · Cited by 171
A monoclonal antibody specific for cells of the melanocyte lineage.
Vennegoor, C., Hageman, P., Nouhuijs, H. M. P.-V., Ruiter, D. J., Calafat, J., Ringens, P. J., & Rümke, P. (1988) · Europe PMC (PubMed Central) · Cited by 140
Slingluff, C. L., Cox, A. L., Henderson, R. A., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.7.2955 · Cited by 122
Adema, G. J., de Boer, A. J., Hullenaar, R. V., Denijn, M., Ruiter, D. J., VOGEL, A. M., & Figdor, C. G. (1993) · PubMed Central · Cited by 102
Self-citationKatano, M., Saxton, R. E., Cochran, A. J., & Irie, R. F. (1984) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00402467 · Cited by 34
Sequential Chemoimmunotherapy in the Treatment of Metastatic Melanoma
Richards, J. M., Mehta, N., Ramming, K., et al. (1992) · Springer eBooks · doi:10.1007/978-3-642-48715-6_91 · Cited by 16
Cited by
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Self-citationCoulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Self-citationHuman tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Metadata
- Authors
- Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-03-01
- Volume
- 179
- Issue
- 3
- Pages
- 1005-1009
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2008494452
- Cited by
- 589
- References
- 21
- FWCI
- 19.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.